Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is positioned for continued revenue growth, particularly with the anticipated launches of zanidatamab and tarlatamab in China, alongside sustained contributions from existing products like Xgeva, Kyprolis, Blincyto, and Pobevcy. The company's core drug, Brukinsa, is favored over competing BTK inhibitors, which could drive peak sales to approximately $7.1 billion, supported by strong prescription volume and a seasonal rebound in sales dynamics. Additionally, the ongoing advancement of next-generation therapies such as sonro and ‘673 may further bolster revenue despite anticipated pricing pressures, suggesting a robust long-term growth outlook for BeOne Medicines.

Bears say

BeOne Medicines faces a negative outlook primarily due to slower-than-expected uptake for its commercial products, particularly Brukinsa, which significantly contributes to the company's revenue. The biotechnology sector's competitive landscape in hematologic oncology presents challenges, as the company has a high bar to clear for next-generation therapies, increasing the risk of underperformance and impacting overall sales growth. Additionally, substantial cash burn on pipeline initiatives, combined with geopolitical risks and potential IP protection challenges, raises concerns regarding the sustainability of BeOne's financial health and market position.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $374.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $374.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.